Hepatitis C virus (HCV) is a blood-borne pathogen that causes widespread chronic liver disease (1) . In an article in the current issue of Hepatology, Perin et al. identify flunarizine, a clinically approved drug for treating migraine, as an inhibitor of specific HCV genotypes (Fig. 1A) .
Leveraging several experimental approaches, the authors demonstrate that fusion of viral and host-cell membranes during viral entry is the step that is susceptible to flunarizine inhibition.
Determinants of susceptibility to this and related drugs including fluphenazine, pimozide, and trifluoperizine (Fig. 1B) reside in the E1 and E2 envelope glycoproteins of HCV. These findings suggest a cost-efficient potential anti-HCV therapeutic strategy and shed light on the mechanism of HCV cell entry.
HCV is an enveloped positive-sense single-stranded RNA virus from the hepacivirus genus in the Flaviviridae family. In the bloodstream of infected patients it travels in association with lipoprotein particles. HCV is highly hepatotropic and follows a complex entry pathway reliant on multiple host entry factors (2) . Following attachment and trafficking to tight junctions in polarized hepatocytes, the virus is internalized and fusion of the viral and endosomal membranes proceeds by mechanism dependent on the reduced pH of the endosomal lumen. Once HCV genome is delivered to the cytoplasm, a single polyprotein is translated and processed into three structural and seven non-structural proteins. Genome replication and egress of newly formed virions complete the lifecycle. Several recently approved anti-HCV drugs target viral polyprotein processing and genome replication (3).
HCV E1 and E2 are the two envelope glycoproteins required for cellular attachment and membrane fusion. E1 and E2 form stable heterodimers and are anchored in the viral membrane by their C-terminal transmembrane domains. Recent structural studies revealed that HCV E1 and E2 proteins have molecular architectures distinct from the envelope proteins of other viruses from other genera within the Flaviviridae family (4-6). E2 contains the determinants of attachment while E1 has been proposed to contain the determinants of fusion. However, the molecular trajectory leading to membrane fusion is not fully understood due in part to the lack of a complete three-dimensional structure of the E1/E2 heterodimer.
More than a decade before the discovery of HCV, flunarizine was developed as a calcium antagonist with potential applications in treatment of vascular disorders (7). In the 1980s it found widespread use as an effective anti-migraine therapeutic and is still used in this capacity in 
